Literature DB >> 15081254

Autoantibodies against cerebral muscarinic cholinoceptors in Sjögren syndrome: functional and pathological implications.

Silvia Reina1, Leonor Sterin-Borda, Betina Orman, Enri Borda.   

Abstract

Previous studies have demonstrated that antibodies against muscarinic acetylcholine receptors (mAChRs) from exocrine glands, correlates with Sjögren syndrome (SS) in the majority of patients. The aim of the present investigation was to establish if serum IgG antibodies present in SS interacts with cerebral mAChRs. Results show that anti-cerebral IgG are present in the sera of 40% SS patients studied. Autoantibodies were able to interact with mAChRs of cerebral frontal cortex membranes inhibiting the [(3)H]QNB binding to its specific receptor. Moreover, tested by ELISA and dot blot they recognized the synthetic peptides corresponding to the second extracellular loop of human M(1) and M(3) mAChR. In addition, the corresponding affinity-purified anti-M(1) and anti-M(3) peptide IgGs displayed an agonistic activity, stimulating phosphoinositide hydrolysis. The results support the notion that serum IgG autoantibodies in SS patients target cerebral mAChRs may have some role in the pathogenesis of higher cognitive dysfunction present in SS patients.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15081254     DOI: 10.1016/j.jneuroim.2004.01.019

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  7 in total

1.  Atorvastatin inhibits the inflammatory response caused by anti-M(3) peptide IgG in patients with primary Sjögren's syndrome.

Authors:  Silvia Reina; Daniela Passafaro; Leonor Sterin-Borda; Enri Borda
Journal:  Inflammopharmacology       Date:  2012-03-23       Impact factor: 4.473

2.  Primary Sjogrens syndrome is associated with impaired autonomic response to orthostasis and sympathetic failure.

Authors:  W-F Ng; A J Stangroom; A Davidson; K Wilton; S Mitchell; J L Newton
Journal:  QJM       Date:  2012-09-13

3.  Layered peptide arrays: high-throughput antibody screening of clinical samples.

Authors:  Gallya Gannot; Michael A Tangrea; John W Gillespie; Heidi S Erickson; Benjamin S Wallis; Rose Anne Leakan; Vladimir Knezevic; Dan P Hartmann; Rodrigo F Chuaqui; Michael R Emmert-Buck
Journal:  J Mol Diagn       Date:  2005-10       Impact factor: 5.568

4.  Parameters of Somatosensory Evoked Potentials in Patients with Primary Sjӧgren's Syndrome: Preliminary Results.

Authors:  Edyta Dziadkowiak; Agata Sebastian; Małgorzata Wieczorek; Elżbieta Kusińska; Marta Waliszewska-Prosół; Piotr Wiland; Maria Ejma
Journal:  J Immunol Res       Date:  2018-04-05       Impact factor: 4.818

Review 5.  Autonomic Nervous System Dysfunction in Primary Sjögren's Syndrome.

Authors:  Kristen Davies; Wan-Fai Ng
Journal:  Front Immunol       Date:  2021-07-26       Impact factor: 7.561

6.  Autonomic symptoms are common and are associated with overall symptom burden and disease activity in primary Sjogren's syndrome.

Authors:  Julia L Newton; James Frith; Danielle Powell; Kate Hackett; Katharine Wilton; Simon Bowman; Elizabeth Price; Colin Pease; Jacqueline Andrews; Paul Emery; John Hunter; Monica Gupta; Saravanan Vadivelu; Ian Giles; David Isenberg; Peter Lanyon; Adrian Jones; Marian Regan; Annie Cooper; Robert Moots; Nurhan Sutcliffe; Michele Bombardieri; Costantino Pitzalis; John McLaren; Steven Young-Min; Bhaskar Dasgupta; Bridget Griffiths; Dennis Lendrem; Sheryl Mitchell; Wan-Fai Ng
Journal:  Ann Rheum Dis       Date:  2012-05-05       Impact factor: 19.103

7.  Reduction of [11C](+)3-MPB binding in brain of chronic fatigue syndrome with serum autoantibody against muscarinic cholinergic receptor.

Authors:  Shigeyuki Yamamoto; Yasuomi Ouchi; Daisaku Nakatsuka; Tsuyoshi Tahara; Kei Mizuno; Seiki Tajima; Hirotaka Onoe; Etsuji Yoshikawa; Hideo Tsukada; Masao Iwase; Kouzi Yamaguti; Hirohiko Kuratsune; Yasuyoshi Watanabe
Journal:  PLoS One       Date:  2012-12-11       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.